Aclaris Therapeutics, Inc. $ACRS Shares Sold by Walleye Capital LLC

Key Points

• Walleye Capital LLC reduced its stake in Aclaris Therapeutics by 56.6%, selling 407,185 shares in the first quarter, resulting in ownership of approximately 0.29% of the company valued at $477,000.
• Institutional investors hold 98.34% of Aclaris Therapeutics' stock, with notable recent investments from companies like Invesco Ltd. and Graham Capital Management L.P.
• Aclaris Therapeutics has garnered a consensus rating of "Buy" among analysts, with a current target price averaging $8.71, despite the stock trading at $1.99.

Walleye Capital LLC decreased its stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 56.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 311,712 shares of the biotechnology company's stock after selling 407,185 shares during the quarter. Walleye Capital LLC owned approximately 0.29% of Aclaris Therapeutics worth $477,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Invesco Ltd. bought a new position in shares of Aclaris Therapeutics during the 4th quarter valued at approximately $28,000. Graham Capital Management L.P. purchased a new position in Aclaris Therapeutics during the fourth quarter valued at approximately $35,000. Alpine Global Management LLC bought a new position in shares of Aclaris Therapeutics in the fourth quarter worth approximately $38,000. Alps Advisors Inc. boosted its position in shares of Aclaris Therapeutics by 36.4% in the first quarter. Alps Advisors Inc. now owns 78,782 shares of the biotechnology company's stock worth $121,000 after purchasing an additional 21,022 shares during the period. Finally, Velan Capital Investment Management LP purchased a new stake in shares of Aclaris Therapeutics in the fourth quarter worth $67,000. Institutional investors own 98.34% of the company's stock.

Aclaris Therapeutics Stock Up 1.4%

Aclaris Therapeutics stock traded up $0.03 during midday trading on Friday, reaching $2.10. The stock had a trading volume of 749,118 shares, compared to its average volume of 726,335. The firm has a market cap of $227.50 million, a price-to-earnings ratio of -1.53 and a beta of 0.27. Aclaris Therapeutics, Inc. has a 52-week low of $1.05 and a 52-week high of $5.17. The company has a fifty day moving average of $1.67 and a 200 day moving average of $1.55.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.13). Aclaris Therapeutics had a negative return on equity of 34.01% and a negative net margin of 802.03%.The firm had revenue of $1.78 million during the quarter, compared to analyst estimates of $1.34 million. Equities research analysts predict that Aclaris Therapeutics, Inc. will post -0.82 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on ACRS. Scotiabank lowered their target price on shares of Aclaris Therapeutics from $15.00 to $9.00 and set a "sector outperform" rating on the stock in a research note on Friday, May 9th. Piper Sandler began coverage on Aclaris Therapeutics in a research note on Thursday, July 10th. They issued an "overweight" rating and a $6.00 price objective for the company. HC Wainwright reiterated a "buy" rating and set a $16.00 target price on shares of Aclaris Therapeutics in a research report on Wednesday, June 25th. Finally, Wedbush reissued an "outperform" rating and issued a $8.00 price target on shares of Aclaris Therapeutics in a report on Monday, June 23rd. One equities research analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $8.71.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.